NTRB Stock Overview
Nutriband Inc. develops a portfolio of transdermal pharmaceutical products.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Nutriband Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.85 |
| 52 Week High | US$5.93 |
| 52 Week Low | US$1.53 |
| Beta | 0.44 |
| 1 Month Change | 41.28% |
| 3 Month Change | 42.33% |
| 1 Year Change | 6.94% |
| 3 Year Change | -75.05% |
| 5 Year Change | -87.15% |
| Change since IPO | -31.94% |
Recent News & Updates
Recent updates
Is Nutriband (NASDAQ:NTRB) A Risky Investment?
Mar 31
Is Nutriband (NASDAQ:NTRB) Weighed On By Its Debt Load?
Sep 13Nutriband GAAP EPS of -$0.12, revenue of $0.5M
Sep 08Nutriband opens a new branch in Ecuador with plans to expand into the South American market
Jul 22Nutriband: Advancing Transdermal Delivery Of Injectable Drugs
Nov 01Does Nutriband (NASDAQ:NTRB) Have A Healthy Balance Sheet?
Oct 06Shareholder Returns
| NTRB | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -9.8% | 0.9% | 1.2% |
| 1Y | 6.9% | 13.9% | 24.7% |
Return vs Industry: NTRB underperformed the US Pharmaceuticals industry which returned 13.9% over the past year.
Return vs Market: NTRB underperformed the US Market which returned 24.7% over the past year.
Price Volatility
| NTRB volatility | |
|---|---|
| NTRB Average Weekly Movement | 14.8% |
| Pharmaceuticals Industry Average Movement | 9.9% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: NTRB's share price has been volatile over the past 3 months.
Volatility Over Time: NTRB's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | n/a | Gareth Sheridan | nutriband.com |
Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. Its lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. The company also develops other products, which include AVERSA buprenorphine and AVERSA methylphenidate; exenatide for type 2 diabetes; and follicle stimulating hormone for infertility.
Nutriband Inc. Fundamentals Summary
| NTRB fundamental statistics | |
|---|---|
| Market cap | US$30.12m |
| Earnings (TTM) | -US$5.28m |
| Revenue (TTM) | US$2.09m |
15.6x
P/S Ratio-6.2x
P/E RatioIs NTRB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NTRB income statement (TTM) | |
|---|---|
| Revenue | US$2.09m |
| Cost of Revenue | US$1.28m |
| Gross Profit | US$810.27k |
| Other Expenses | US$6.09m |
| Earnings | -US$5.28m |
Last Reported Earnings
Oct 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.62 |
| Gross Margin | 38.80% |
| Net Profit Margin | -253.02% |
| Debt/Equity Ratio | 38.7% |
How did NTRB perform over the long term?
See historical performance and comparison